Phase II trial of gefitinib in recurrent glioblastoma
- Author
- RICH, Jeremy N; REARDON, David A; KAO, James C; STENZEL, Timothy T; RASHEED, B. K; TOURT-UHLIG, Sandra E; HERNDON, James E; VREDENBURGH, James J; SAMPSON, John H; FRIEDMAN, Allan H; BIGNER, Darell D; FRIEDMAN, Henry S; PEERY, Terry; DOWELL, Jeannette M; QUINN, Jennifer A; PENNE, Kara L; WIKSTRAND, Carol J; VAN DUYN, Lauren B; DANCEY, Janet E; MCLENDON, Roger E
Departments of Medicine, Surgery, Pathology, and Cancer Center Biostatistics, Duke University Medical Center, Durham, NC, United States
National Cancer Institute, Bethesda, MD, United States - Source
Journal of clinical oncology. 2004, Vol 22, Num 1, pp 133-142, 10 p ; ref : 33 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Anticancéreux Cancérologie Essai clinique phase II Glioblastome Géfitinib Récidive Gliome malin Système nerveux central pathologie Système nerveux pathologie Tumeur maligne
- Keyword (en)
- Antineoplastic agent Cancerology Phase II trial Glioblastoma Gefitinib Relapse Malignant glioma Central nervous system disease Nervous system diseases Malignant tumor
- Keyword (es)
- Anticanceroso Cancerología Ensayo clínico fase II Glioblastoma Gefitinib Recaida Glioma maligno Sistema nervosio central patología Sistema nervioso patología Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17E Tumors of the nervous system. Phacomatoses
- Discipline
- Neurology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 16078166
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2004.08.110 
https://dx.doi.org/10.1200/JCO.2004.08.110
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2004.08.110\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"133\";s:8:\"\u0000*\u0000epage\";s:3:\"142\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"RICH\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeremy N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:16:\"REARDON, David A\";i:1;s:12:\"KAO, James C\";i:2;s:18:\"STENZEL, Timothy T\";i:3;s:13:\"RASHEED, B. K\";i:4;s:21:\"TOURT-UHLIG, Sandra E\";i:5;s:16:\"HERNDON, James E\";i:6;s:20:\"VREDENBURGH, James J\";i:7;s:15:\"SAMPSON, John H\";i:8;s:17:\"FRIEDMAN, Allan H\";i:9;s:16:\"BIGNER, Darell D\";i:10;s:17:\"FRIEDMAN, Henry S\";i:11;s:12:\"PEERY, Terry\";i:12;s:19:\"DOWELL, Jeannette M\";i:13;s:17:\"QUINN, Jennifer A\";i:14;s:13:\"PENNE, Kara L\";i:15;s:18:\"WIKSTRAND, Carol J\";i:16;s:18:\"VAN DUYN, Lauren B\";i:17;s:15:\"DANCEY, Janet E\";i:18;s:17:\"MCLENDON, Roger E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2004.08.110\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"133\";s:8:\"\u0000*\u0000epage\";s:3:\"142\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"RICH\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeremy N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:16:\"REARDON, David A\";i:1;s:12:\"KAO, James C\";i:2;s:18:\"STENZEL, Timothy T\";i:3;s:13:\"RASHEED, B. K\";i:4;s:21:\"TOURT-UHLIG, Sandra E\";i:5;s:16:\"HERNDON, James E\";i:6;s:20:\"VREDENBURGH, James J\";i:7;s:15:\"SAMPSON, John H\";i:8;s:17:\"FRIEDMAN, Allan H\";i:9;s:16:\"BIGNER, Darell D\";i:10;s:17:\"FRIEDMAN, Henry S\";i:11;s:12:\"PEERY, Terry\";i:12;s:19:\"DOWELL, Jeannette M\";i:13;s:17:\"QUINN, Jennifer A\";i:14;s:13:\"PENNE, Kara L\";i:15;s:18:\"WIKSTRAND, Carol J\";i:16;s:18:\"VAN DUYN, Lauren B\";i:17;s:15:\"DANCEY, Janet E\";i:18;s:17:\"MCLENDON, Roger E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2004.08.110\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2004.08.110\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"133\";s:8:\"\u0000*\u0000epage\";s:3:\"142\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"RICH\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeremy N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:16:\"REARDON, David A\";i:1;s:12:\"KAO, James C\";i:2;s:18:\"STENZEL, Timothy T\";i:3;s:13:\"RASHEED, B. K\";i:4;s:21:\"TOURT-UHLIG, Sandra E\";i:5;s:16:\"HERNDON, James E\";i:6;s:20:\"VREDENBURGH, James J\";i:7;s:15:\"SAMPSON, John H\";i:8;s:17:\"FRIEDMAN, Allan H\";i:9;s:16:\"BIGNER, Darell D\";i:10;s:17:\"FRIEDMAN, Henry S\";i:11;s:12:\"PEERY, Terry\";i:12;s:19:\"DOWELL, Jeannette M\";i:13;s:17:\"QUINN, Jennifer A\";i:14;s:13:\"PENNE, Kara L\";i:15;s:18:\"WIKSTRAND, Carol J\";i:16;s:18:\"VAN DUYN, Lauren B\";i:17;s:15:\"DANCEY, Janet E\";i:18;s:17:\"MCLENDON, Roger E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:23:\"10.1200\/JCO.2004.08.110\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"22\";s:8:\"\u0000*\u0000issue\";s:1:\"1\";s:8:\"\u0000*\u0000spage\";s:3:\"133\";s:8:\"\u0000*\u0000epage\";s:3:\"142\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:4:\"RICH\";s:10:\"\u0000*\u0000aufirst\";s:8:\"Jeremy N\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:16:\"REARDON, David A\";i:1;s:12:\"KAO, James C\";i:2;s:18:\"STENZEL, Timothy T\";i:3;s:13:\"RASHEED, B. K\";i:4;s:21:\"TOURT-UHLIG, Sandra E\";i:5;s:16:\"HERNDON, James E\";i:6;s:20:\"VREDENBURGH, James J\";i:7;s:15:\"SAMPSON, John H\";i:8;s:17:\"FRIEDMAN, Allan H\";i:9;s:16:\"BIGNER, Darell D\";i:10;s:17:\"FRIEDMAN, Henry S\";i:11;s:12:\"PEERY, Terry\";i:12;s:19:\"DOWELL, Jeannette M\";i:13;s:17:\"QUINN, Jennifer A\";i:14;s:13:\"PENNE, Kara L\";i:15;s:18:\"WIKSTRAND, Carol J\";i:16;s:18:\"VAN DUYN, Lauren B\";i:17;s:15:\"DANCEY, Janet E\";i:18;s:17:\"MCLENDON, Roger E\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:53:\"Phase II trial of gefitinib in recurrent glioblastoma\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
